However, anti-PD-1 monoclonal antibodies by blocking the interaction of PD-1 with its ligands, PD-L1/PD-L2, reinvigorate the anti-tumor T cell responses and enhancing anti-tumor immunity [6]. Here, PDCD1LG2 is linked to neoplasm.